Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

PEOPLE - Franklin Ophthalmic Instruments (US) has announced several management changes:

This article was originally published in Clinica

  • News

Executive Summary

Franklin Ophthalmic Instruments (US) has announced several management changes, as part of its new corporate structure as Franklin.MOI. Robert Davis, past president and CEO, has resigned as chairman of the board and director. Michael Carroll has been appointed CEO, in addition to his earlier appointment as president. James Urban, who was earlier named senior vice-president and COO, has been elected chairman of the board. Dallas Talley has resigned from the board. Brian Carroll has been appointed CFO. He was formerly controller of Midwest Ophthalmic Instruments (MOI) and a co-founder of the ORIMS division of Midwest and Doctor's Financial Services.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT091409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By